Our work aligns with recent studies defining a double hit gene signature20,32 and may explain why as many as 30% of patients with DLBCL have concurrent overexpression of MYC and BCL2 mRNA or protein (double expression) independent of DH/TH translocation status. Here, MYC is linked to diffuse large B-cell lymphoma.